Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) is now available.
CARsgen Therapeutics Holdings Ltd. announced its annual results for 2024, reporting a revenue of approximately RMB39.4 million, primarily from its BCMA CAR T-cell product. Despite achieving a gross profit of RMB14.7 million, the company faced a net loss of RMB798 million, an increase from the previous year, attributed to higher net other losses and reduced R&D expenses. The company’s cash reserves decreased to RMB1,479 million, with expectations of maintaining adequate cash flow into 2028.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company focused on the development of innovative CAR-T cell therapies. The company specializes in autologous BCMA CAR T-cell products, with a market focus on cancer treatment.
YTD Price Performance: 49.19%
Average Trading Volume: 8,523,933
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$7.28B
For a thorough assessment of 2171 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue